You do not have permission to access this chart.
Please Sign Up or Login

About:

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women’s health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

214

Address:

Myovant Sciences Ltd. 11-12 St. James’s Square Suite 1 3rd Floor London SW1Y 4LB United Kingdom

Website:

Purpose-driven Science

Phone:

44 20 7400 3351

Leave a comment

Your email address will not be published. Required fields are marked *